Latest News

  • 06.20.14 - Title: Utilizing Media to Reduce the Burden of Cervical Cancer ... read more »
  • 06.02.14 - APRIL 2014 – The World Health Organization Strategic Advisory Group ... read more »
  • 05.02.14 - Twelve years into a 16-year randomized controlled study, researchers report ... read more »

Read more news stories »

News

Fighting Cervical Cancer in Little Haiti through Film

Title: Utilizing Media to Reduce the Burden of Cervical Cancer in Little Haiti: A Community-Based Participatory Research Approach

Authors: Brigette Frett, Myra Aquino, Marie Fatil, Julia Seay, Dinah Trevil, Michèle Jessica Fièvre, Valentine Cesar, Erin Kobetz

These two educational short films discuss cervical cancer prevention through HPV vaccination and Pap testing for a Haitian audience. These films were written and produced by a Haitian writer and star Kreyol-speaking actors, incorporating medical and public health information shared by partners at the University of ...

Read More

News Category: Global, National

The WHO Strategic Advisory Group of Experts on Immunization recommends a 2-dose HPV vaccination schedule

APRIL 2014 – The World Health Organization Strategic Advisory Group of Experts on Immunization recommends a 2-dose HPV vaccination schedule for girls that initiate vaccination prior to 15 years of age. The recommended minimal interval between the 2 doses is 6 months, but it may be extended to 12 months.

A 3-dose schedule (i.e. at 0, 1-2, and 6 months) continues to be recommended if immunization is initiated after the girl’s 15th birthday or if the individual is immunocompromised, including those ...

Read More

News Category: Global, National

Results from VIA Screening Study Show Promise for Reducing Cervical Cancer Mortality in India

Twelve years into a 16-year randomized controlled study, researchers report that the use of VIA screening by primary health workers in Mumbai, India is showing significant results. Visual inspection of the cervix with ascetic acid (VIA) is an inexpensive screening method, and its low cost makes it a viable option for women in India, many of whom do not have access to Pap smears. The results of this study have shown a statistically significant 31% reduction in cervical cancer mortality ...

Read More

News Category: Global

Recent Study Examines HPV-Based Versus Cytology-Based Screening for Cervical Cancer

A recently released study on the effectiveness of HPV-based versus cytology-based screening for cervical cancer showed that HPV-based screening provides 60–70% greater protection against invasive cervical carcinomas compared with cytology. The study included several years of follow-up of women in four randomized trials to investigate these outcomes. As the study authors write, “Data of large-scale randomized trials support initiation of HPV-based screening from age 30 years and extension of screening intervals to at least 5 years.

 

Read the study abstract here:

Read More

News Category: Global, National

FDA Approves First HPV Test for Primary Cervical Cancer Screening

On April 24 the U.S. Food and Drug Administration approved the first FDA-approved HPV DNA test for women 25 and older that can be used alone to help a health care professional assess the need for a woman to undergo additional diagnostic testing for cervical cancer. The test also can provide information about the patient’s risk for developing cervical cancer in the future. This approval “offers women and physicians a new option for cervical cancer screening,” said Alberto Gutierrez, Ph.D., ...

Read More

News Category: National

Researchers at the Ohio State University Determine How HPV May Lead to Cervical Cancer Development

A study published in Genome Research and reviewed in The Scientist explains that researchers at the Ohio State University have determined a new way that HPV might lead to cervical cancer development. Using the supercomputing power available at Ohio State, researchers did extensive genome sequencing, which allowed them to see “in vivid detail that HPV can damage host-cell genes and chromosomes at sites of viral insertion,” said co-senior author David Symer, M.D., Ph.D., assistant professor of molecular virology, immunology and ...

Read More

News Category: National

New Research Shows Quadrivalent HPV Vaccine is Safe Among Women with HIV

Data published in Clinical Infectious Diseases show that that the quadrivalent HPV vaccine is safe and immunogenic in women aged 13 to 45 with HIV. As Erna Milunka Kojic, MD, associate professor of medicine at Brown University, told Infectious Disease News, “HIV-infected women carry a disproportionate burden of HPV-associated diseases,” so this new information will benefit an important at-risk group.

 

Read more about the newly released research on the use of the quadrivalent HPV vaccine in women with HIV:

http://www.healio.com/infectious-disease/vaccine-preventable-diseases/news/online/%7Ba98e11bc-1d7c-4467-9de7-8e59c85d753d%7D/quadrivalent-hpv-vaccine-effective-in-women-with-hiv

Read More

News Category: Global, National

Gates Foundation Grant Awarded to CDC Foundation and George W. Bush Institute to Address Global Cervical Cancer

A $3.6 million grant from the Bill and Melinda Gates Foundation will allow the George W. Bush Institute, the CDC and the World Health Organization to work with the Pink Ribbon Red Ribbon® initiative to improve the monitoring and evaluation of cervical cancer screening and treatment programs.

The primary activities of this two-year grant include:

The conduct of rapid baseline situational assessments with reports and strategic consultations with countries to process the results and develop recommendations for improved monitoring and evaluation; and The ...

Read More

News Category: Funding, Global, National

Debate Surrounding the FDA Review of an Alternative to Pap Test for Cervical Cancer Screenings

Seventeen patient advocacy groups, including Consumers Union, the Cancer Prevention and Treatment Fund and the National Alliance for Hispanic Health have submitted a letter to the FDA expressing concern over a new HPV DNA test. The test, which would be recommended for women age 25 and older, is currently under FDA review. Opponents of the test cite its expense (much more than a Pap test) and the potential for confusion over screening recommendations, which may lead to over or under ...

Read More

News Category: National

FDA Panel Recommends New HPV DNA Test for Primary Cervical Cancer Screening

On March 12, 2014 a Food and Drug Administration (FDA) advisory panel unanimously recommended that FDA approve a new HPV DNA test for primary screening of cervical cancer in the US. The new test, developed by Roche, is recommended for women aged 25 and older, and can detect high-risk HPV, as well as high-risk HPV types 16 and 18. Several distinguished guests spoke in favor of HPV primary screening, including Dr. Mark Schiffman from the National Cancer Institute, Dr. Walter ...

Read More

News Category: National

preloaded image 0 preloaded image 1 preloaded image 2 preloaded image 3 preloaded image 4 preloaded image 5 preloaded image 6 preloaded image 7